Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.6219
-0.0333 (-5.08%)
At close: Nov 13, 2026, 4:00 PM EST
0.6518
+0.0299 (4.81%)
After-hours: Nov 13, 2026, 5:11 PM EST
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
2.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
| Dec 31, 2021 | 449.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.72M |
| Curis | 4.31M |
| BioRestorative Therapies | 357.87K |
| VivoSim Labs | 112.00K |
| Jupiter Neurosciences | 64.69K |
| Ernexa Therapeutics | 1.00K |
CLDI News
- 38 minutes ago - Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 17 days ago - Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories - GlobeNewsWire
- 25 days ago - Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 - GlobeNewsWire
- 7 weeks ago - Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency - GlobeNewsWire
- 1 month ago - Calidi prices 1.025M shares at $1.17 in registered direct offering - TheFly
- 1 month ago - Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire